Mono PTY Gun (Bard) at Dr. Essa Lab

Mono PTY Gun (Bard) at Dr. Essa Lab

The Mono PTY Gun (Bard) is a state-of-the-art, disposable, spring-loaded core needle biopsy instrument designed to capture high-quality, intact tissue specimens from various organs and soft tissue masses. Manufactured by Bard, a global leader in medical device technology, this automated biopsy system is widely recognized for its clinical precision, reliability, and safety. At Dr. Essa Lab, this advanced diagnostic tool is utilized by highly experienced interventional radiologists and pathologists to perform minimally invasive core needle biopsies. The primary objective of using the Mono PTY Gun (Bard) is to obtain a sufficient volume of tissue to facilitate accurate histopathological analysis, which is crucial for distinguishing between benign and malignant lesions, identifying inflammatory conditions, and guiding personalized treatment strategies.

The mechanical design of the Mono PTY Gun (Bard) features a high-speed, spring-loaded firing mechanism that rapidly propels a sharp cutting cannula over an inner specimen notch. This rapid action ensures clean, sharp cuts through dense or fibrous tissues, minimizing tissue shear and preserving the cellular architecture of the specimen. Preserving tissue architecture is a critical advantage over fine-needle aspiration (FNA), as it allows pathologists at Dr. Essa Lab to perform detailed immunohistochemistry (IHC) and molecular testing. The procedure is commonly performed under the guidance of real-time imaging modalities, such as high-resolution ultrasound or computed tomography (CT), ensuring that the needle is precisely positioned within the target lesion while avoiding adjacent vital structures.

The clinical value of a core biopsy performed with the Mono PTY Gun (Bard) cannot be overstated. By providing a definitive tissue diagnosis, this procedure eliminates the diagnostic ambiguity often associated with cytological smears. It serves as a cornerstone in oncology, hepatology, nephrology, and breast health, offering patients a minimally invasive alternative to open surgical biopsies. This translates to significantly reduced patient anxiety, minimal physical trauma, no surgical scarring, and a much faster recovery time, allowing patients to return to their daily activities almost immediately.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is vital to ensure safety, minimize the risk of complications, and guarantee the diagnostic quality of the tissue sample. Prior to undergoing a biopsy with the Mono PTY Gun (Bard) at Dr. Essa Lab, patients must adhere to the following guidelines:

• Coagulation Screening: Patients are required to undergo baseline blood tests, including Prothrombin Time (PT), International Normalized Ratio (INR), and Activated Partial Thromboplastin Time (aPTT), to assess blood clotting function and minimize bleeding risks.
• Medication Review: Patients must inform the clinical team of all medications they are currently taking. Anticoagulants, antiplatelet agents, and nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin, warfarin, clopidogrel, or ibuprofen must typically be discontinued 5 to 7 days prior to the procedure, strictly under the supervising physician’s guidance.
• Fasting Requirements: Depending on the target organ and whether conscious sedation or local anesthesia is planned, patients may be instructed to fast (no food or liquids) for 4 to 6 hours before the procedure.
• Medical History and Allergies: Patients must disclose any known allergies, particularly to local anesthetics (like lidocaine), latex, contrast agents, or antiseptic solutions.
• Previous Imaging: It is essential to bring all relevant previous imaging studies, such as ultrasounds, mammograms, CT scans, or MRI reports, to assist the interventional radiologist in precise targeting.
• Comfortable Attire: Patients should wear loose, comfortable two-piece clothing to facilitate easy access to the biopsy site.

During the Procedure

The core needle biopsy procedure using the Mono PTY Gun (Bard) is performed in a sterile, controlled clinical environment at Dr. Essa Lab. The step-by-step process includes:

• Patient Positioning: The patient is positioned comfortably on an examination table. The specific position depends on the target site; for example, supine for a liver or kidney biopsy, prone or lateral decubitus for a breast biopsy, or left lateral decubitus for a prostate biopsy.
• Aseptic Preparation: The skin overlying the target area is thoroughly cleansed with an antiseptic solution (such as chlorhexidine or betadine) and draped with sterile towels to maintain a sterile field.
• Local Anesthesia: A local anesthetic, typically 1% or 2% lidocaine, is infiltrated into the skin and subcutaneous tissues down to the level of the lesion to ensure the patient experiences minimal to no pain during the procedure.
• Imaging Guidance: The interventional radiologist uses real-time ultrasound or CT imaging to visualize the lesion and map the safest trajectory for the biopsy needle.
• Needle Insertion and Firing: A tiny skin nick (1-2 mm) is made with a scalpel. Under direct imaging visualization, the Mono PTY Gun (Bard) needle is advanced to the edge of the target lesion. Once positioned, the spring-loaded mechanism is activated. A distinct clicking sound is heard as the gun rapidly fires and retracts, capturing a high-quality tissue core within milliseconds.
• Specimen Retrieval: The needle is withdrawn, and the intact tissue core is carefully retrieved from the specimen notch and immediately placed in a preservative solution (usually 10% neutral buffered formalin) for transport to the histopathology laboratory. Multiple passes (usually 2 to 5) may be performed to ensure adequate tissue sampling.
• Post-Procedure Care: Manual pressure is applied to the biopsy site for several minutes to achieve complete hemostasis. A sterile adhesive bandage or compression dressing is then applied. The patient is monitored in a recovery area for a brief period before being safely discharged.

When is a Mono PTY Gun (Bard) Performed?

Evaluation of Suspicious Breast Masses

Physicians frequently request a core needle biopsy using the Mono PTY Gun (Bard) when a screening mammogram, breast ultrasound, or breast MRI reveals an indeterminate or highly suspicious lesion classified under BI-RADS category 4 or 5. This includes palpable breast lumps, areas of microcalcification, or architectural distortion. The biopsy is essential to differentiate benign conditions, such as fibroadenomas or fibrocystic changes, from malignant breast cancers, including invasive ductal or lobular carcinoma, thereby guiding surgical planning and oncological therapy.

Investigation of Prostate Nodules and Elevated PSA

In cases where a patient presents with an elevated Prostate-Specific Antigen (PSA) level or abnormal findings on a Digital Rectal Examination (DRE), a transrectal or transperineal ultrasound-guided prostate biopsy is indicated. Utilizing the Mono PTY Gun (Bard) allows clinicians to obtain precise core samples from specific zones of the prostate gland. This assists in detecting prostate adenocarcinoma, determining the Gleason score (which measures tumor aggressiveness), and planning appropriate therapeutic interventions such as active surveillance, surgery, or radiation.

Assessment of Indeterminate Liver and Kidney Lesions

When diagnostic imaging (ultrasound, CT, or MRI) identifies solid or complex cystic masses within the liver or kidneys, a core biopsy is often necessary to establish a definitive diagnosis. For liver lesions, the biopsy helps differentiate hepatocellular carcinoma (HCC) or metastatic disease from benign lesions like focal nodular hyperplasia. For renal masses, it helps identify renal cell carcinoma (RCC) subtypes or benign oncocytomas. It also assists in evaluating diffuse parenchymal diseases, such as non-alcoholic steatohepatitis (NASH), cirrhosis, or glomerulonephritis.

Diagnosis of Soft Tissue Tumors and Lymphadenopathy

Persistent, unexplained enlargement of lymph nodes (lymphadenopathy) or the presence of deep-seated soft tissue masses in the extremities, trunk, or retroperitoneum requires histopathological evaluation. The Mono PTY Gun (Bard) is highly effective in obtaining core samples from these lesions. The preserved tissue architecture allows pathologists to distinguish reactive lymphoid hyperplasia from lymphomas (Hodgkin and non-Hodgkin) and to diagnose various soft tissue sarcomas, which is critical because treatment protocols differ vastly between these conditions.

Characterization of Unexplained Organ Pathology

In patients presenting with unexplained organ dysfunction, such as acute kidney injury of unknown origin, persistent proteinuria, or progressive liver failure, a core biopsy is performed to evaluate the underlying tissue pathology. The high-quality tissue cores obtained by the Mono PTY Gun (Bard) enable detailed microscopic examination, immunofluorescence, and electron microscopy, which are essential for diagnosing specific autoimmune, metabolic, or infectious diseases affecting these vital organs.

What Does a Mono PTY Gun (Bard) Detect?

The histopathological analysis of tissue cores retrieved via the Mono PTY Gun (Bard) can detect a wide spectrum of neoplastic, inflammatory, and infectious conditions, including:

• Invasive Ductal Carcinoma (IDC): The most common form of breast cancer, characterized by malignant epithelial cells penetrating the basement membrane.
• Ductal Carcinoma In Situ (DCIS): Non-invasive breast cancer confined to the milk ducts.
• Fibroadenoma: A common, benign, fibroepithelial breast tumor.
• Prostate Adenocarcinoma: Malignant transformation of prostate glandular tissue, graded using the Gleason scoring system.
• Benign Prostatic Hyperplasia (BPH): Non-malignant nodular growth of the prostate gland.
• Hepatocellular Carcinoma (HCC): Primary malignancy of the liver cells, often arising in the setting of chronic cirrhosis.
• Hepatic Steatosis: Accumulation of lipids within hepatocytes (fatty liver).
• Renal Cell Carcinoma (RCC): Primary malignant tumor of the renal parenchymal tubules.
• Renal Oncocytoma: A benign renal epithelial tumor that can mimic renal cell carcinoma on imaging.
• Metastatic Carcinoma: Secondary tumor deposits in lymph nodes or organs originating from a primary cancer elsewhere in the body.
• Hodgkin Lymphoma: Malignancy of the lymphatic system characterized by the presence of Reed-Sternberg cells.
• Non-Hodgkin Lymphoma: A diverse group of blood cancers that develop from lymphocytes.
• Soft Tissue Sarcoma: Malignant tumors originating in mesenchymal tissues such as muscle, fat, or blood vessels.
• Granulomatous Tuberculosis: Chronic infectious granulomas characterized by caseating necrosis and Langhans giant cells.
• Chronic Active Hepatitis: Ongoing inflammation of the liver parenchyma, often due to Hepatitis B or C.
• Liver Cirrhosis: Advanced diffuse fibrosis and regenerative nodule formation in the liver.
• Atypical Ductal Hyperplasia (ADH): A borderline breast lesion associated with an increased risk of developing breast cancer.
• Lobular Carcinoma In Situ (LCIS): Abnormal cell growth within the lobules of the breast.
• Glomerulonephritis: Immune-mediated inflammatory diseases affecting the renal glomeruli.
• Amyloidosis: Extracellular deposition of abnormal amyloid proteins in organs like the kidney or liver.
• Focal Nodular Hyperplasia (FNH): A benign, regenerative liver lesion characterized by a central stellate scar.
• Lipoma: A benign tumor composed of mature adipose tissue.
• Chronic Interstitial Nephritis: Inflammation of the interstitial spaces of the kidney, often drug-induced.
• Suppurative Abscess: Localized accumulation of pus and necrotic debris caused by bacterial infection.

Turnaround Time and Report Access at Dr. Essa Lab

At Dr. Essa Lab, we understand that waiting for biopsy results can be an anxious time for patients and their families. Once the tissue core is obtained using the Mono PTY Gun (Bard), it is immediately placed in formalin and transported to our centralized histopathology laboratory. The tissue undergoes a meticulous preparation process, including dehydration, paraffin embedding, microtome sectioning, and staining (typically Hematoxylin and Eosin). If necessary, advanced immunohistochemical (IHC) stains are applied to confirm the diagnosis.

The standard turnaround time for a histopathology report at Dr. Essa Lab is typically 3 to 5 working days. Complex cases requiring specialized stains, decalcification, or expert second opinions may take slightly longer to ensure absolute diagnostic accuracy. Once finalized, reports are thoroughly reviewed and signed off by our board-certified consultant pathologists. Patients and referring physicians can easily access and download the highly detailed diagnostic reports online through the secure Dr. Essa Lab web portal or mobile application, ensuring seamless integration into the patient’s ongoing clinical care plan.

Mono PTY Gun (Bard) Findings Overview

The following table outlines the typical clinical parameters evaluated during a core biopsy using the Mono PTY Gun (Bard), comparing normal tissue characteristics with potential pathological findings:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Breast Tissue Architecture	Normal lobules, ducts, and specialized stroma without atypia or malignancy.	Invasive Ductal Carcinoma, Ductal Carcinoma In Situ (DCIS), Fibroadenoma, atypical hyperplasia.
Prostate Parenchyma	Normal fibromuscular stroma and glandular epithelium; no evidence of malignancy.	Prostate Adenocarcinoma (Gleason score 6-10), Benign Prostatic Hyperplasia (BPH), prostatitis.
Liver Parenchyma	Normal hepatic lobules, portal triads, and hepatocytes with preserved architecture.	Hepatocellular Carcinoma, metastatic disease, cirrhosis, severe steatohepatitis, chronic active hepatitis.
Renal Cortex & Medulla	Normal glomeruli, tubules, interstitium, and blood vessels; no significant pathology.	Renal Cell Carcinoma (RCC), glomerulonephritis, interstitial nephritis, amyloidosis.
Lymph Node Structure	Preserved nodal architecture with normal germinal centers and sinus histiocytosis.	Hodgkin Lymphoma, Non-Hodgkin Lymphoma, metastatic carcinoma deposits, granulomatous lymphadenitis.
Soft Tissue Masses	Normal skeletal muscle, adipose tissue, or fibrous connective tissue.	Liposarcoma, leiomyosarcoma, fibrosarcoma, benign lipoma, nodular fasciitis.
Coagulation Parameters (Pre-test)	PT/INR and aPTT within standard reference ranges; adequate platelet count.	Prolonged PT/INR or aPTT, thrombocytopenia (increased risk of post-biopsy hematoma).

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Mono PTY Gun (Bard)?

• Experienced Healthcare Professionals: Our interventional radiologists and board-certified pathologists possess extensive expertise in performing and interpreting core needle biopsies.
• Patient-Focused Care: We prioritize patient comfort, safety, and emotional well-being throughout the entire biopsy procedure.
• Quality Diagnostic Services: Dr. Essa Lab utilizes state-of-the-art histopathology equipment and strict quality control protocols to ensure maximum diagnostic accuracy.
• Professional Reporting: Our pathology reports are highly detailed, structured, and compliant with international diagnostic standards (such as CAP guidelines).
• Modern Diagnostic Approach: We employ advanced imaging modalities (ultrasound/CT) to guide the Mono PTY Gun (Bard) with pinpoint precision.
• Comfortable Environment: Our diagnostic centers are designed to provide a clean, sterile, and welcoming environment for patients undergoing interventional procedures.
• Convenient Location: With an extensive network of branches across Karachi and other major cities, accessing our diagnostic services is highly convenient.
• Commitment to Accurate Diagnosis: Established in 1987, Dr. Essa Lab has built a legacy of trust, offering reliable diagnostic insights that guide effective clinical decisions.